Security record · archived quarter
NVCR
Novocure Ltd · Healthcare · Medical - Devices
13Tracked holders
—Δ holders
14.57MShares held
$249.63MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 90 | 0 | 75.20M | $1.14B | +6 | −6 |
| Q1 2026 | 93 | -1 | 69.74M | $759.20M | +6 | −7 |
| Q4 2025 | 93 | -2 | 74.88M | $967.62M | — | −2 |
| Q3 2025 | 19 | 0 | 56.46M | $729.50M | — | — |
| Q2 2025 | 16 | +1 | 59.30M | $1.06B | +2 | −1 |
| Q1 2025 | 12 | -3 | 16.40M | $292.30M | — | −3 |
| Q4 2024 | 15 | +1 | 16.08M | $479.25M | +1 | — |
| Q3 2024 | 13 | 0 | 14.54M | $227.34M | — | — |
| Q2 2024 | 13 | — | 14.57M | $249.63M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 2.38M | — | $40.70M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.38M | — | $40.70M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Capital World Investors ✦ | 2.31M | — | $39.54M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 2.16M | — | $36.93M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 2.16M | — | $36.93M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Baillie Gifford ✦ | 1.69M | — | $28.91M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 1.69M | — | $28.91M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 1.69M | — | $28.91M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Baillie Gifford ✦ | 1.69M | — | $28.91M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 1.24M | — | $21.31M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Millennium Management ✦ | 1.21M | — | $20.66M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Renaissance Technologies ✦ | 760.17K | — | $13.02M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 699.29K | — | $11.98M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Coatue Management ✦ | 608.67K | — | $10.43M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 516.86K | — | $8.85M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 516.86K | — | $8.85M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 497.47K | — | $8.52M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 431.44K | — | $7.39M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 431.44K | — | $7.39M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 431.44K | — | $7.39M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 81.28K | — | $1.39M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 221 holders, 97.96M shares, $1.02B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API